Format

Send to

Choose Destination
Front Immunol. 2017 Apr 21;8:442. doi: 10.3389/fimmu.2017.00442. eCollection 2017.

Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis.

Author information

1
Department of Neurology, Columbia University Medical Center, New York, NY, USA.
2
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
3
Department of Pharmacology, Columbia University Medical Center, New York, NY, USA.
4
Columbia Translational Neuroscience Initiative, Columbia University Medical Center, New York, NY, USA.

Abstract

Antibodies against neuronal receptors and synaptic proteins are associated with autoimmune encephalitides (AE) that produce movement and psychiatric disorders. In order to exert their pathological effects on neural circuits, autoantibodies against central nervous system (CNS) targets must gain access to the brain and spinal cord by crossing the blood-brain barrier (BBB), a tightly regulated gateway formed by endothelial cells lining CNS blood vessels. To date, the pathogenic mechanisms that underlie autoantibody-triggered encephalitic syndromes are poorly understood, and how autoantibodies breach the barrier remains obscure for almost all AE syndromes. The relative importance of cellular versus humoral immune mechanisms for disease pathogenesis also remains largely unexplored. Here, we review the proposed triggers for various autoimmune encephalopathies and their animal models, as well as basic structural features of the BBB and how they differ among various CNS regions, a feature that likely underlies some regional aspects of autoimmune encephalitis pathogenesis. We then discuss the routes that antibodies and immune cells employ to enter the CNS and their implications for AE. Finally, we explore future therapeutic strategies that may either preserve or restore barrier function and thereby limit immune cell and autoantibody infiltration into the CNS. Recent mechanistic insights into CNS autoantibody entry indicate promising future directions for therapeutic intervention beyond current, short-lived therapies that eliminate circulating autoantibodies.

KEYWORDS:

NMDA receptor; Sydenham’s chorea; autoantibodies; autoimmune encephalitis; basal ganglia encephalitis; blood–brain barrier; dopamine receptor; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center